Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

NCT07367685 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Refractory B-cell Lymphoma

Interventions

BIOLOGICAL: QH103 Cell Injection
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

The Second Affiliated Hospital of Fujian Medical University